Find a TenderAwarded

Published 18 Jul 2023, 08:39 BST

Official UK procurement notice

NP92619 ERT Medicines · UK public procurement notice

Authority: The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS") (NHS & healthcare)

Goods

Sectors: Medical Devices & Pharma (33) Delivery: Scotland (UKM)

Awarded value£9,709,875published contract · exc. VAT

Awarded 7 Aug 2019

Awarded to Takeda UK Limited

Contract term 4 yrsends 30 Sept 2023 · starts 1 Oct 2019

What is being bought

Published requirement description

No description was published on the notice. See the official documents.

CPV: Pharmaceutical products

The lotProcurement structure

single lot · no lot value published

Lot #1The following Framework Agreements have been extended and are for the supply of the… 4 yrs

The following Framework Agreements have been extended and are for the supply of the following ERT Medicines to NHS Scotland: NP92619 (e) - Velaglucerase alfa - VPRIV®, NP92619 (f) - Idursulfase - Elaprase®, NP92619 (g) - Agalsidase Alfa - Replagal®.

Contract period: 1 Oct 2019 – 30 Sept 2023 (4 yrs)

Delivery: Scotland · All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.

33600000 Pharmaceutical products

Procedure terms & legal framework

From the official record · publisher note attached

Legal basis: CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
Procurement category: Goods
Notice status: Awarded
Procurement threshold: Unspecified in notice
Regulatory regime: Standard
Commercial structure: Stand-alone contract (no framework)
Competition type: Competitive procedure
GPA / WTO covered: Unspecified in notice
Recurring procurement: Unspecified in notice
First published: 18 Jul 2023, 08:39 BST
Last source update: 18 Jul 2023, 08:39 BST
Authority reference: NP92619 (e-g)
FTS notice number: 2023/S 000-020565
Classification (CPV): Pharmaceutical products
Delivery area: Scotland (UKM)
Official registry OCID: ocds-h6vhtk-03e2c3 Find a Tender

Review and risk notes

Review procedure: Economic operators should approach the contracting authority in the first instance. However, the only formal remedy is to apply to the courts:
An economic operator that suffers, or is at risk of suffering, loss, or damage attributable to a breach of duty under the Public Contracts (Scotland) Regulations 2015 or the Procurement Reform (Scotland) Act 2014, may bring proceedings in the Sheriff Court or the Court of Session.
The bringing of court proceedings against the Authority after the Framework Agreement has been entered into will not affect the Framework Agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the Framework Agreement has been entered into are limited to the award of damages.

Publisher note: The estimated values of the Framework Agreements referred to in Section V.2.4 covers the twenty one (21) month contract duration and the twenty seven (27) month extension period of the Framework Agreement. OJEU notice numbers for each of the individual Awards: NP92619 (e)VPRIV®- 2019/S 170-415138 NP92619 (f)Elaprase®- 2019/S 170-415129 NP92619 (g)Replagal®- 2019/S 170-415117 (SC Ref:737956)

How it was run

Official notice

Submission deadline: —

Timeline

1 Oct 2019 → 18 Jul 2023 · 2 dates

Contract starts
1 Oct 2019, 00:00 BST
Notice published
18 Jul 2023, 08:39 BST

Commercial outcome & contract awards

Published awards, contracts and bid statistics, not a forecast

Awards 1

Awarded value £9,709,8751 contract exc. VAT

Contracts signed 1latest 7 Aug 2019

Awarded to	Value	Date	Status
Takeda UK LimitedSME	£9,709,875 †	—	Awarded

Contracts

NP92619 ERT Medicines · Takeda UK LimitedSME
Signed
7 Aug 2019
Value
£9,709,875
Period
… – 30 Sept 2023
Status
active
- Change This modification effects an extension of the Framework Agreement duration from 01 October 2023 until 30 September 2024. The modification notice covers the individual Framework Agreements. All Terms and Conditions of Contract remain in place., Need for modification brought about by circumstances which a diligent contracting authority/entity could not foresee: This modification is necessary to meet the additional demands of the Scottish Health and Social Care sector during the Covid-19 pandemic and associated recovery, to maintain supply and remove unnecessary disruption from the Authority due to circumstances unforeseen by the Authority in line with Regulation 72(1)(c) of the Public Contracts (Scotland) Regulations 2015.

Contracting authority & participating public bodies

The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")

Contracting authorityNHS & healthcare Gyle Square (NSS Head Office), 1 South Gyle Crescent, Edinburgh, Scotland, EH12 9EBContact name, email

Dispute resolution & review bodies

Sheriff Court HouseReview body EdinburghContact email

Bidders & participating suppliers

1 commercial party on the notice

Takeda UK LimitedAwarded supplier Takeda House, Mercury Park, Wycombe Lane, Wooburn Green, High Wycombe, Bucks, UK, HP10 0HH

Official documents & specifications

Official links; attachments are not copied

No document links were published on the notice.